Harbin Pharmaceutical Hits Day High with 10.09% Surge Amid Market Decline

Harbin Pharmaceutical Group Co., Ltd. has experienced a significant uptick in its stock performance, gaining 10.09% on July 13, 2026. The stock reached an intraday high of CNY 3.71, showcasing notable activity in the pharmaceuticals and biotechnology sector. In terms of performance metrics, Harbin Pharmaceutical has outperformed the China Shanghai Composite index over various time frames. Over the past week, the stock has risen by 16.67%, and over the past month, it has increased by 17.41%. Year-to-date, the stock has shown a positive return of 7.54%, contrasting with the composite index's decline of 1.39%. However, the stock's one-year performance remains in the negative territory at -3.89%, while its three-year and five-year performances are at 15.58% and 28.37%, respectively. Despite the recent gains, the company has faced challenges, including a significant decline in earnings per share and lower operating cash flow. The current market capitalization stands at CNY 7,830 million, with a price-to-earnings ratio of 23.00.